Loading
Cancer Research and Treatments · Journal article
Eurasian Journal of Oncology and Radiology · August 7, 2026
The material analysed did not support any firm read.
This is a narrative literature review that synthesizes existing knowledge on the classification, molecular features, and clinical significance of gastroesophageal junction tumors and small intestinal bacterial overgrowth in colorectal cancer patients. The review itself contains no original data, quantitative results, or comparative evidence and serves only to outline the scope and gaps in current literature.
Narrative literature review. Published literature on esophagogastric junction tumors and SIBO in colorectal cancer patients.
High prevalence of SIBO in colorectal cancer patients, particularly after surgical treatment and during anticancer therapy SIBO associated with increased gastrointestinal symptoms, impaired nutritional status, reduced quality of life, and potential impact on oncological treatment effectiveness
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies SIBO as a clinically significant comorbidity in colorectal cancer that warrants diagnosis and treatment, but provides no evidence-based guidance on prevalence rates, diagnostic thresholds, or management outcomes to inform clinical practice.
This is a narrative literature review that summarizes existing publications on gastroesophageal junction tumors and SIBO in colorectal cancer, but presents no original data, effect sizes, or quantitative findings to evaluate.
As stated by the source record.
This review identifies SIBO as a clinically significant comorbidity in colorectal cancer that warrants diagnosis and treatment, but provides no evidence-based guidance on prevalence rates, diagnostic thresholds, or management outcomes to inform clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Relevance: Small intestinal bacterial overgrowth (SIBO) is a common disorder of the intestinal microbiota that can significantly affect gastrointestinal function, immune response, and metabolism. In patients with colorectal cancer (CRC), the risk of developing SIBO is increased due to anatomical and functional alterations of the intestine, the oncological process itself, surgical interventions, and chemo- and radiotherapy. Despite the growing interest in the role of the gut microbiota in CRC carcinogenesis and disease course, the prevalence, pathogenetic significance, and clinical consequences of SIBO in this patient population remain insufficiently studied.The study aimed to analyze and summarize current literature data on the prevalence, mechanisms of development, diagnostic approaches, and clinical significance of small intestinal bacterial overgrowth in patients with colorectal cancer.Materials and Methods: A structured narrative literature review was conducted for the period from January 2016 to June 2026. Publications were searched in the PubMed and Google Scholar databases using the following keywords: esophagogastric junction, adenocarcinoma, Siewert classification, American Joint Committee on Cancer/Tumor-Node-Metastasis (AJCC/TNM), molecular subtypes, The Cancer Genome Atlas (TCGA), proteomics, and personalized therapy. Full-text English-language publications containing data on the anatomical and topographic classification, molecular heterogeneity, clinicoprognostic significance, and therapeutic perspectives of esophagogastric junction tumors were included in the review.Results: The literature analysis demonstrated a high prevalence of SIBO in patients with CRC, particularly after surgical treatment and during anticancer therapy. SIBO was associated with increased gastrointestinal symptoms, impaired nutritional status, reduced quality of life, and a potential impact on the effectiveness of oncological treatment. Current diagnostic methods and approaches to the management of SIBO are discussed.Conclusion: SIBO is a clinically significant condition in patients with CRC and requires timely diagnosis and a comprehensive treatment approach. Further studies are needed to develop standardized management algorithms for this patient population.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.